Background: Pulmonary hypertension (PH) is a disease that affects the adult or infant population. Dehydroepiandrosterone (DHEA), a steroid hormone, has been previously shown to prevent and to reverse PH in an adult rat model. We thus investigated its effect in a rat-pup model of chronic hypoxic PH. Methods: Animals were maintained for 3 wk in a hypobaric chamber to induce PH, with or without concomitant treatment with DHEA (30 mg/kg every alternate day). results: DHEA significantly reduced mean pulmonary artery pressure (measured by right cardiac catheterization), pulmonary artery remodeling (evaluated by histology), and rightventricular hypertrophy (measured by echography and by the Fulton index). At the level of the pulmonary artery smooth muscle cell (PASMC), DHEA increased activity and expression of the large-conductance Ca2+-activated potassium channel (BK Ca ) (assessed by means of the patch clamp technique). DHEA also inhibited both serotonin-and KCl-induced contraction and smooth muscle cell proliferation. conclusion: Collectively, these results indicate that DHEA prevents PH in infant rats and may therefore be clinically relevant for the management of PH in human infants. P ulmonary hypertension (PH) is a disease that affects both adults and infants. PH is characterized by increased pulmonary vascular pressure and resistance, which can lead, in rare cases in infants, to right-ventricular failure and ultimately to death (1). Increased reactivity to agonists and remodeling of small pulmonary arteries (PAs) are landmarks of PH (2,3). In infants, there are a variety of PH phenotypes, some of which are specific to this age group: (i) PH secondary to congenital heart disease with a left-right shunt, (ii) persistent PH of the newborn due to the absence of a drop in neonatal pulmonary resistance, (iii) acute or chronic pulmonary disease induced by hypoxemia, and (iv) idiopathic forms (4, 5) . Pharmacological treatments that mainly aim at vasodilating PAs, e.g., prostanoid analog, endothelin receptor antagonists, or phosphodiesterase inhibitors (2,6), still need to be comprehensively evaluated in pediatric patients. It is thus essential to develop new treatments to prevent and/or reverse PH in this population.
P
ulmonary hypertension (PH) is a disease that affects both adults and infants. PH is characterized by increased pulmonary vascular pressure and resistance, which can lead, in rare cases in infants, to right-ventricular failure and ultimately to death (1) . Increased reactivity to agonists and remodeling of small pulmonary arteries (PAs) are landmarks of PH (2, 3) . In infants, there are a variety of PH phenotypes, some of which are specific to this age group: (i) PH secondary to congenital heart disease with a left-right shunt, (ii) persistent PH of the newborn due to the absence of a drop in neonatal pulmonary resistance, (iii) acute or chronic pulmonary disease induced by hypoxemia, and (iv) idiopathic forms (4, 5) . Pharmacological treatments that mainly aim at vasodilating PAs, e.g., prostanoid analog, endothelin receptor antagonists, or phosphodiesterase inhibitors (2, 6) , still need to be comprehensively evaluated in pediatric patients. It is thus essential to develop new treatments to prevent and/or reverse PH in this population.
Dehydroepiandrosterone (DHEA) is the most abundant adrenal steroid, and serum concentration of its sulfate ester is approximately 20-fold higher than that of any other circulating steroid hormone (7, 8) . In different models of adult rats with PH, we (9) and others (10, 11) have shown that DHEA prevents and reverses PH and the resulting right-ventricular (RV) hypertrophy as well as small PA remodeling. However, similar studies have not been performed in newborn or infant animals. We have thus investigated the effect of DHEA in a model of infant rats in which PH was induced. We have observed that chronic treatment with DHEA (30 mg/kg every alternate day) is able to prevent PH and its associated cardiovascular alterations such as RV hypertrophy, pulmonary vascular hyperreactivity, and smooth muscle cell proliferation.
RESULTS

Beneficial Effect of DHEA on the Juvenile Rat Model of PH
Exposure to chronic hypoxia (CH) for 3 wk induced PH in juvenile rats (CH rats), as revealed by the increase in mean pulmonary artery pressure (PAP) (27 ± 3.2 mm Hg, n = 8, vs. 14.7 ± 2.3 mm Hg, n= 6, P < 0.05, in CH and control rats, respectively) (Figure 1a) . CH also induced RV hypertrophy, as demonstrated by a significant increase (75%) in the RV thickness measured by cardiac echography (Figure 1b) . Furthermore, the pulmonary artery acceleration time decreased, confirming the presence of PH in infants (Figure 1c) . Chronic treatment of CH rats with DHEA (assessed by the rise in its circulating concentration to 503 ± 311 nmol/l (n = 5)) prevented CH-induced PH. Indeed mean PAP, RV thickness, and the pulmonary artery acceleration time of CH-DHEA rats were not significantly different from those of control rats (Figure 1a-c) . These data demonstrate that DHEA treatment prevented the pulmonary hemodynamic changes induced by CH.
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Because remodeling and hyperreactivity of PA are hallmarks of PH in adults, we next studied the effect of DHEA on these characteristics in infants.
Antiremodeling Effect of DHEA in the Pulmonary Vasculature
CH-induced PH is thus characterized by a remodeling of the pulmonary vasculature due to smooth muscle hypertrophy (Figure 2a) . Morphometric analyses of vascular wall thickness showed that CH increased this parameter by 33% in small PAs (61.5 ± 1% in control rats vs. 81.7 ± 0.8% in CH rats) (Figure 2a,b) . DHEA significantly prevented this CH-induced increase in vessel wall thickness (66.4 ± 0.8%) (Figure 2a,b) . All the above results confirm that DHEA treatment prevents PA remodeling associated with PH.
We then studied the effect of DHEA on in vitro proliferation of pulmonary artery smooth muscle cells (PASMCs) induced by three different mitogens: fetal calf serum (FCS), serotonin (5-HT) (a well-known mitogenic agent in PASMCs) (12) (13) (14) , and hypoxia. Dose-dependent proliferation induced by FCS was inhibited by DHEA (50 µmol/l, Figure 3a) . Exposure of PASMCs to 30 μmol/l 5-HT for 24 h also induced a significant proliferation (twofold increase), albeit of lesser magnitude as compared with 10% FCS. This 5-HT-induced proliferation was inhibited by the additional presence of DHEA (50 µmol/l) in the culture medium (Figure 3b) . Finally, we observed that hypoxia (10% oxygen, 5% CO 2 for 24 h) potentiated the proliferative effect of FCS (0.2-10%), and again the additional presence of DHEA prevented this effect (Figure 3c ).
DHEA Reduced PA Contractile Responses to Serotonin and KCl
We evaluated the effect of two vasoconstrictor agents 5-HT and KCl, each acting via different membrane mechanisms: a G protein-coupled membrane receptor-dependent pathway and a direct membrane depolarization, respectively. Both agents induced concentration-dependent contractile responses in intrapulmonary arteries (IPAs) from control rats (Figure 4a,b) . In IPAs from CH rats, the response to 5-HT was markedly increased as compared with those of control rats (Figure 4a) . The efficacy (E max ) of 5-HT increased by 80.5% (p <.0.05). However, the potency (EC 50 ) was not significantly altered (4.1 ± 0.4 and 4.6 ± 0.5 µmol/l, respectively). In IPAs from CH-DHEA rats, 5-HT-induced contraction was statistically reduced for low concentrations (EC 50 : 11 ± 0.4 µmol/l) (Figure 4a ). Regarding KCl (60 mmol/l), the efficacy was not significantly altered by CH, but its potency was increased (EC 50 = 18 ± 1.5 mmol/l and 32 ± 2.8 mmol/l in CH and control rats, respectively, p < 0.05) Figure 1 . Chronic DHEA treatment prevents chronic hypoxia-induced PH in juvenile rats. Chronic hypoxia (CH) exposure for 3 wk induced (a) a significant increase in mean PAP, (b) a significant increase in RV wall thickness, and (c) a decrease in pulmonary artery acceleration time value. DHEA treatment (30 mg/kg orally every alternate day, CH-DHEA juvenile rats) prevented all these changes. Each bar represents the mean value ± SEM from 6 to 12 animals. *P < 0.05 vs. CH. DHEA, dehydroepiandrosterone; NS, not significant; PAP, pulmonary artery pressure; PH, pulmonary hypertension; RV, right-ventricular. Contraction and thus hyperreactivity of PAs are, at least in part, dependent on the membrane potential value, which is mainly governed by the activity of potassium channels (15, 16) . The amplitude of whole-cell potassium currents elicited from a holding potential from −80 mV was decreased in PASMCs from CH but increased in PASMCs from CH-DHEA rats as compared with control rats (Figure 5a,b,d ). This outward current is a mix of voltage-gated (Kv) and calcium-activated (K Ca ) potassium current. On the one hand, iberiotoxin (100 nmol/l), a selective inhibitor of BK Ca (17) , decreased outward currents (34 ± 5% of inhibition at + 50 mV) (Figure 5c) , whereas, on the other hand, residual current was almost entirely inhibited by 4-aminopyridine (5 mmol/l), a nonspecific inhibitor of K V channels (Figure 5c) . At a holding potential of −20 mV, which inactivates Kv, the potassium current was mainly a BK Ca current, given that it was inhibited by iberiotoxin (91 ± 5%, in control rats, data not shown). Figure 5e shows that the current density (at a −20 mV holding potential) was significantly decreased in PASMCs from CH rats and largely increased in PASMCs from CH-DHEA rats. These results indicate that chronic DHEA treatment increases mainly BK Ca current. Recording of iberiotoxin-sensitive BK Ca unitary current (180 pS, n = 10) with the cell-attached configuration (pipette filled with the extracellular solution of the whole-cell mode) indicated that DHEA treatment did not change the open probability of the channel (data not shown). However, there were more cell-attached patches in which a current was recorded in CH-DHEA rats than in CH rats (70% and 25%, n = 6 and 12, respectively) indicating that DHEA increased the number of BK Ca channels.
DISCUSSION
The current study shows that, as in adults, DHEA prevents the onset of chronic hypoxia-induced PH in juvenile rats. More specifically, DHEA reduces the increase in mean PAP and prevents associated PA remodeling and hyperreactivity, as well as RV hypertrophy.
Regarding the animal model, the following two issues deserve discussion. First, our study was conducted in pups aged 15 d whose lung maturation is comparable to the early childhood stage in humans (18) but substantially different from neonatal hypoxic PH described in pups exposed to hypoxia immediately after birth (19, 20) . Our present model aimed to mimic hypoxic PH secondary to chronic or acute respiratory disease in children such as bronchopulmonary dysplasia, acute viral bronchiolitis, or severe pulmonary infection. Second, because our aim was to evaluate the effect of DHEA in PH, we did not include an additional group of healthy juvenile rats treated with DHEA only, because we have previously demonstrated the absence of modification of pulmonary and systemic hemodynamic in air-exposed adult rats treated with DHEA (9) .
The active dose of DHEA used in our experiments is identical to that given in our previous studies (9, 21) . This chronic oral protocol yields a circulating concentration of DHEA in the range of ≥10 −7 mol/l, similar to that commonly used in in vitro studies. Therefore our data are of pharmacological relevance (9) .
In adults, PA remodeling is one of the main causes of increased pulmonary vascular resistance in PH. Likewise, in the present study, in juvenile rats, CH induced PA remodeling as a consequence of an increase in vascular wall thickness. This effect was prevented by DHEA treatment (Figure 2) . Remodeling of PA during PH in adult animals as well as in humans is mainly a result of increased proliferation of PASMCs (22, 23) . We addressed the possible effect of DHEA on this key step in the development of PH in infants by studying the proliferation of PASMCs in vitro. The stimulating effect of FCS, 5-HT, or hypoxia was, in each case, prevented by the additional presence of DHEA in the culture medium (Figure 3) . The proliferative actions of 5-HT or hypoxia on PASMCs have mainly been ascribed to their effect on the RhoA/ROCK pathway or on hypoxia inducible factor1a levels, respectively (24-26). Of note, DHEA has also 
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Articles been shown to inhibit RhoA/ROCK pathway and to decrease hypoxia inducible factor-1a in PASMCs (11, 27) . PA hyperreactivity is an additional key feature in PH. In the present study, we have shown that DHEA prevents CH-induced hyperactivity to 5-HT and KCl (Figure 4) . The effect of DHEA on 5-HT-induced contraction may involve an effect on a signaling pathway that mobilizes intracellular calcium (9) given that we have previously demonstrated that CH modifies resting cytosolic calcium concentration and agonist-induced contraction in PASMCs from the adult rat (28) . The effect of DHEA on KCl-induced contraction may involve ionic conductance because CH depolarizes the cell membrane and downregulates potassium channels in adult rat and human PASMCs (29, 30) . Likewise, in the present study, we have shown that CH decreases potassium currents in PASMCs from juvenile rats and that this effect is prevented following DHEA treatment. The major component of the potassium current increase is related to an increased number of BK Ca s in CH-DHEA rats. This result is in accordance with a previous study conducted in adult rats (9) revealing an increase in BK Ca expression in PASMCs from CH-DHEA rats in comparison with CH rats. Finally, the acute application of DHEA relaxed KCl-preconstricted arterial rings in a concentration-dependent manner (Figure 4c) , suggesting an inhibitory effect of DHEA on voltage-dependent calcium channels. This latter result is also in agreement with a recent finding showing that DHEA inhibits T-type calcium channels in PASMCs from adult rat (31) .
The beneficial effect of DHEA in PH has also been observed in the monocrotaline-induced PH rat model, which is closer to the pathophysiology of idiopathic PH (11) , although further studies investigating its effect on plexiform lesions remain to be performed. With respect to the mechanism of action, in addition to the modulation of Ca 2+ -activated potassium channel expression and activity, other cellular mechanisms have already been demonstrated and include a protective effect on the vascular endothelium (32) , an activation of the RhoA/Rho kinase signaling pathway (11), a decrease in vascular remodeling with activation of apoptosis, and a decrease in cellular proliferation via the inhibition of transcription factors such as hypoxia inducible factor-1 or nuclear factor of activated T cell (27, 33) .
In adult humans, we recently demonstrated, in a pilot study conducted in PH associated with chronic obstructive pulmonary disease, the excellent clinical tolerance of DHEA in general and particularly regarding the respiratory status (34) . In conclusion, the present study indicates that DHEA displays some preventive actions on PH in a juvenile rat model. Owing to its lack of side effects, it could be assumed that DHEA may prove to be a valuable molecule that deserves further clinical studies in PH secondary to respiratory diseases in infants.
METHODS
Animals and Chronic Hypoxia Exposure
The investigation was carried out in agreement with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH) (NIH Publication No. 85-23, revised 1996) and approved by the local institutional animal care and use committee (protocol number: AP 2/11/2005, Bordeaux 2 University). Fifteen days after birth, Wistar female rats with their pups were randomized and separated into three groups. The first group (control) was housed in ambient room air, the second group (CH) was exposed to chronic hypoxia for 3 wk in a hypobaric chamber (50 kPa), and the third group (CH-DHEA) was exposed to chronic hypoxia and was treated concomitantly with DHEA (30 mg/kg orally every alternate day). Animals were killed after the exposition phase immediately prior to in vitro or following in vivo experiments, which were performed according to the following protocols.
Assessment of PH: Hemodynamic and Echocardiographic
Measurements PAP was measured in anesthetized and closed-chest rats with 2.5-Fr catheters (Vigon SA, Ecouen, France) inserted through the right jugular vein then through the right atria and the right ventricle into the PA as previously described (35) . Echocardiography measurements were also conducted as previously described (36) . M-mode measurement of RV thickness was performed in a trans-ventricular short-axis view at the level of the papillary muscles. The pulmonary artery acceleration time was measured from the time of onset of systolic flow to peak pulmonary outflow velocity.
Histology
For morphometric studies, vessel rings were fixed in 4% formaldehyde solution. Multiple 5-μm transverse slides were processed in paraffin wax and stained with hematoxylin and eosin, elastic stain, and orcein-picroindigo-carmine. Area of the entire vessel (VA), area of the lumen (LA), and percentage vessel wall thickness [(VA − LA) / VA × 100] were measured in 80-100 μm PA as previously described (37) . Fifty measurements were made per rat by an investigator blinded to the treatment groups.
Isolation and Culture of PASMCs
IPAs (first-and second-order branches) of juvenile rats were mechanically dissected. Freshly isolated PASMCs and cultured PASMCs were obtained using an enzymatic dissociation method already described (38, 39) . Cells were used between 2 and 24 h after isolation for electrophysiology or later for cell proliferation assay. Smooth muscle characteristics of isolated cells were confirmed by positive immunostaining with an anti-α smooth muscle actin antibody (Sigma, Saint Quentin Fallavier, France).
Electrophysiological Recordings
Channel activity was recorded from cell-attached or whole-cell patches using the technique described by Hamill et al. (40) and previously applied to PASMCs (12, 38) . Stimulus control, data acquisition, analysis, and processing were carried out on a PC computer using Pclamp 10 software (Molecular Devices, Foster City, CA). Current density was expressed as the maximum amplitude of the current per capacitance unit. For whole-cell recording, the bathing solution was composed of the following (in mmol/l): 5 KCl, 140 NaCl, 2.2 CaCl 2 , 1.2 MgCl 2 , 14 D-glucose, and 10 N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (pH = 7.4, adjusted with NaOH), and the pipette solution had the following composition (in mmol/l): 5 NaCl, 50 KCl, 65 K 2 SO 4 , 2 MgCl 2 , 2 ATP, and 10 N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid, (pH 7.3, adjusted with KOH). For cellattached recordings, the bating solution included the following (in mmol/l): 140 KCl, 2.2 CaCl 2 , 1.2 MgCl 2 , 14 D-glucose, and 10 N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (pH = 7.4, adjusted with KOH), and the pipette solution had the following composition (in mmol/l): 140 NaCl, 2.2 CaCl 2 , 1.2 MgCl 2 , 14 D-glucose, and 10 N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (pH = 7.4, adjusted with NaOH). Drugs were delivered to the cells via pressure ejection from a glass pipette. All experiments were performed at room temperature.
